222 / 236
REFERENCES
1. RAGWITEKTM (Short Ragweed Pollen Allergen Extract) tablet for sublingual
use prescribing information. Available at:
http://www.merck.com/product/usa/ pi_circulars/r/ragwitek/ragwitek_pi.pdf .Accessed December 26, 2014.
2. GRASTEK (Timothy Grass Pollen Allergen Extract). Available at:
http://www. fda.gov/downloads/BiologicsBloodVaccines/Allergenics/UCM393184.pdf .Ac-
cessed December 14, 2014.
3. ORALAIR (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky
Blue Grass Mixed Pollens Allergen Extract). Available at:
http://www.fda. gov/downloads/BiologicsBloodVaccines/Allergenics/UCM391580.pdf .Accessed
April 26, 2015.
4.
Lin SY, Erekosima N, Kim JM, Ramanathan M, Suarez-Cuervo C, Chelladurai Y, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA 2013;309:1278-88.
5.
Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009;123:167-73.e7.
6.
Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/ European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol 2013;131:1288-96.e3 .7.
Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di Lorenzo G. Efficacy of sub- cutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. J Allergy Clin Immunol 2012;130:1097-107 .8.
Dretzke J, Meadows A, Novielli N, Huissoon A, Fry-Smith A, Meads C. Subcu- taneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. J Allergy Clin Immunol 2013;131:1361-6.
9.
Chelladurai Y, Suarez-Cuervo C, Erekosima N, Kim JM, Ramanathan M, Segal JB, et al. Effectiveness of subcutaneous versus sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. J Allergy Clin Immunol 2013;1:361-9 .10.
Kim JM, Lin SY, Suarez-Cuervo C, Chelladurai Y, Ramanathan M, Segal JB, et al. Allergen-specific immunotherapy for pediatric asthma and rhinoconjuncti- vitis: a systematic review. Pediatrics 2013;131:1155-67 .11.
Chelladurai Y, Lin SY. Effectiveness of subcutaneous versus sublingual immuno- therapy for allergic rhinitis: current update. Curr Opin Otolaryngol Head Neck Surg 2014;22:211-5 .12.
Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011;66:740-52 .13.
Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007;(1):CD001936 .14.
Meadows A, Kaambwa B, Novielli N, Huissoon A, Fry-Smith A, Meads C, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess 2013;17:vi, xi-xiv, 1-322 .15.
Piazza I, Bizzaro N. Humoral response to subcutaneous, oral, and nasal immuno- therapy for allergic rhinitis due to Dermatophagoides pteronyssinus. Ann Allergy 1993;71:461-9 .16.
Quirino T, Iemoli E, Siciliani E, Parmiani S, Milazzo F. Sublingual versus injec- tive immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy 1996;26:1253-61 .17.
Mungan D, Misirligil Z, Gurbuz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma—a placebo controlled study. Ann Allergy Asthma Immunol 1999;82: 485-90 .18.
Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immuno- therapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004;59:45-53 .19.
Mauro M, Russello M, Incorvaia C, Gazzola GB, Di Cara G, Frati F. Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study. Eur Ann Allergy Clin Immunol 2007;39:119-22 .20.
Antunez C, Mayorga C, Corzo JL, Jurado A, Torres MJ. Two year follow-up of immunological response in mite-allergic children treated with sublingual immu- notherapy. Comparison with subcutaneous administration. Pediatr Allergy Immu- nol 2008;19:210-8 .21.
Tahamiler R, Saritzali G, Canakcioglu S, Ozcora E, Dirican A. Comparison of the long-term efficacy of subcutaneous and sublingual immunotherapies in perennial rhinitis. ORL J Otorhinolaryngol Relat Spec 2008;70:144-50 .22.
Ventura MT, Carretta A, Tummolo RA, Buquicchio R, Arsieni A, Murgia N. Clin- ical data and inflammation parameters in patients with cypress allergy treated with sublingual swallow therapy and subcutaneous immunotherapy. Int J Immu- nopathol Pharmacol 2009;22:403-13 .23.
Eifan AO, Akkoc T, Yildiz A, Keles S, Ozdemir C, Bahceciler NN, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immu- notherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy 2010;40:922-32 .24.
Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo- controlled, double-blind, double-dummy study. Int Arch Allergy Immunol 2011;157:288-98 .25.
Keles S, Karakoc-Aydiner E, Ozen A, Izgi AG, Tevetoglu A, Akkoc T, et al. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes. J Allergy Clin Immunol 2011;128:808-15.e7 .26.
Aasbjerg K, Backer V, Lund G, Aasbjerg K, Backer V, Lund G, et al. Immu- nological comparison of allergen immunotherapy tablet treatment and subcu- taneous immunotherapy against grass allergy. Clin Exp Allergy 2014;44: 417-28 .27.
Devillier P, Dreyfus JF, Demoly P, Calderon MA. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. BMC Med 2014;12:71.
28.
Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012;129:717-25.e5 .29.
Strunk RC, Sternberg AL, Szefler SJ, Zeiger RS, Bender B, Tonascia J. Long-term budesonide or nedocromil treatment, once discontinued, does not alter the course of mild to moderate asthma in children and adolescents. J Pediatr 2009;154:682-7 .30.
Creticos PS, Esch RE, Couroux P, Gentile D, D’Angelo P, Whitlow B, et al. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol 2014;133:751-8 .31.
Bergmann KC, Demoly P, Worm M, Fokkens WJ, Carrillo T, Tabar AI, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol 2014;133:1608-14.e6 .32.
Mosbech H, Deckelmann R, de Blay F, Pastorello EA, Trebas-Pietras E, Andres LP, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2014;134:568-75.e7 .33.
Nolte H, Maloney J, Nelson HS, Bernstein DI, Lu S, Li Z, et al. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. J Allergy Clin Immunol 2015;135: 1494-501.e6 .34.
Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117: 802-9 .35.
Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338-45 .36.
Mosbech H, Canonica GW, Backer V, de Blay F, Klimek L, Broge L, et al. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. Ann Allergy Asthma Immunol 2015;114:134-40.e1 .37.
Didier A, Worm M, Horak F, Sussman G, de Beaumont O, Le Gall M, et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immu- notherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 2011;128:559-66 .38.
Schwab JA, Wolf H, Schnitker J, Wustenberg E. Safety and tolerability of an intra-seasonal initiation of the SQ-standardised grass allergy immuno- therapy tablet: a non-interventional observational study investigating the feasibility during routine administration. Clin Drug Investig 2013;33: 719-26 .39.
Reich K, Gessner C, Kroker A, Schwab JA, Pohl W, Villesen H, et al. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis. Clin Ther 2011;33:828-40 .40. Medication Guide RAGWITEKTM (RAG-wi-tek (Short Ragweed Pollen
Allergen Extract). Available at:
http://www.merck.com/product/usa/pi_circulars/ r/ragwitek/ragwitek_mg.pdf .Accessed May 2, 2015.
J ALLERGY CLIN IMMUNOL
VOLUME
nnn
, NUMBER
nn
LI ET AL
200